JP2006523672A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006523672A5 JP2006523672A5 JP2006506481A JP2006506481A JP2006523672A5 JP 2006523672 A5 JP2006523672 A5 JP 2006523672A5 JP 2006506481 A JP2006506481 A JP 2006506481A JP 2006506481 A JP2006506481 A JP 2006506481A JP 2006523672 A5 JP2006523672 A5 JP 2006523672A5
- Authority
- JP
- Japan
- Prior art keywords
- treatment
- aminoisobutyric acid
- pharmaceutical composition
- prevention
- animal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- QCHPKSFMDHPSNR-UHFFFAOYSA-N 3-aminoisobutyric acid Chemical compound NCC(C)C(O)=O QCHPKSFMDHPSNR-UHFFFAOYSA-N 0.000 claims 33
- 238000000034 method Methods 0.000 claims 27
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 16
- 238000011282 treatment Methods 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 239000013543 active substance Substances 0.000 claims 13
- 239000002207 metabolite Substances 0.000 claims 13
- 239000000651 prodrug Substances 0.000 claims 13
- 229940002612 prodrug Drugs 0.000 claims 13
- 241001465754 Metazoa Species 0.000 claims 12
- 210000004369 blood Anatomy 0.000 claims 8
- 239000008280 blood Substances 0.000 claims 8
- 235000012000 cholesterol Nutrition 0.000 claims 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 8
- 230000002265 prevention Effects 0.000 claims 8
- 210000001519 tissue Anatomy 0.000 claims 7
- 238000009825 accumulation Methods 0.000 claims 5
- 230000006806 disease prevention Effects 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 235000016709 nutrition Nutrition 0.000 claims 5
- 102000004877 Insulin Human genes 0.000 claims 4
- 108090001061 Insulin Proteins 0.000 claims 4
- 229940125396 insulin Drugs 0.000 claims 4
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- 150000003626 triacylglycerols Chemical class 0.000 claims 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 4
- 102000011690 Adiponectin Human genes 0.000 claims 3
- 108010076365 Adiponectin Proteins 0.000 claims 3
- 208000004930 Fatty Liver Diseases 0.000 claims 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 3
- 206010020772 Hypertension Diseases 0.000 claims 3
- 238000010171 animal model Methods 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 239000008103 glucose Substances 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 238000011321 prophylaxis Methods 0.000 claims 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 230000036765 blood level Effects 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 230000035945 sensitivity Effects 0.000 claims 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010019708 Hepatic steatosis Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 210000000577 adipose tissue Anatomy 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 208000010706 fatty liver disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229910017053 inorganic salt Inorganic materials 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000007863 steatosis Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2003/001463 WO2004091598A1 (en) | 2003-04-18 | 2003-04-18 | Use of beta-aminoisobutyric acid for the treatment of diseases linked to the accumulation of triglycerides and cholesterol |
| PCT/IB2004/001166 WO2004091599A1 (en) | 2003-04-18 | 2004-04-15 | Method for the treatment of diseases linked to an accumulation of triglycerides and cholesterol |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006523672A JP2006523672A (ja) | 2006-10-19 |
| JP2006523672A5 true JP2006523672A5 (https=) | 2007-06-07 |
Family
ID=33187198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006506481A Withdrawn JP2006523672A (ja) | 2003-04-18 | 2004-04-15 | トリグリセリド及びコレステロールの蓄積に結びつけられる疾病の治療方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20060167098A1 (https=) |
| EP (1) | EP1615630A1 (https=) |
| JP (1) | JP2006523672A (https=) |
| AU (1) | AU2003226582A1 (https=) |
| BR (1) | BRPI0409456A (https=) |
| CA (1) | CA2526899A1 (https=) |
| WO (2) | WO2004091598A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8367072B2 (en) * | 2006-12-08 | 2013-02-05 | Polifenoles Naturales, S.L. | Composition for treating obesity and method of using the same |
| CN103298826A (zh) | 2010-11-15 | 2013-09-11 | 特拉维夫大学拉莫特有限公司 | 用于治疗淀粉样纤维形成相关疾病的二肽类似物 |
| CN105250256A (zh) * | 2015-10-16 | 2016-01-20 | 南京医科大学 | β-氨基异丁酸在制备抗糖尿病药物中的应用 |
| KR102646979B1 (ko) * | 2016-03-30 | 2024-03-13 | 마이크로바이오 컴퍼니 엘티디. | 면역 체크포인트 조절제 및 공생 미생물군에 의한 발효 산물로의 병용 암 치료법 |
| JP2019131488A (ja) * | 2018-01-29 | 2019-08-08 | 静岡県公立大学法人 | Ｖｃａｍ−１発現抑制剤、ｍｃｐ−１発現抑制剤、炎症性疾患改善用組成物、加工食品又は飲料 |
| WO2021055564A1 (en) * | 2019-09-17 | 2021-03-25 | Yale University | Methods of treating phosphate concentration disorders with l-baiba |
| CA3215056A1 (en) * | 2021-04-14 | 2022-10-20 | Mingru WANG | Compositions and methods for promoting glycogen synthase activity and augmenting glycogen storage capability |
| EP4337187A4 (en) * | 2021-06-22 | 2024-08-28 | Nanjing Nutrabuilding Bio-Tech Co., Ltd. | Administration of baiba to increase benefit of losing weight of intermittent fasting |
| CN115606809A (zh) * | 2021-10-08 | 2023-01-17 | 南京纽邦生物科技有限公司 | 通过施用β-氨基异丁酸模拟热量限制的生物学益处的方法和组合物 |
| CN116059195A (zh) * | 2022-01-28 | 2023-05-05 | 南京纽邦生物科技有限公司 | 用于提高运动表现或预防或缓解疲劳的组合物和方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4453941A (en) * | 1980-12-29 | 1984-06-12 | Board Of Overseers Of Goshen College | Composition and process for producing pigmentation in hair or skin |
| DE4115468A1 (de) * | 1991-05-11 | 1992-11-12 | Behringwerke Ag | Amidinophenylalaninderivate, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel als antikoagulantien |
| FR2701948B1 (fr) * | 1993-02-22 | 1996-07-26 | Exsymol Sa | Produit de couplage de l'histamine ou l'histamine méthyl-substituée et d'un acide aminé, procédé de préparation et applications thérapeutiques, cosmétologiques et agroalimentaires. |
| JPH07101984A (ja) * | 1993-09-30 | 1995-04-18 | Suntory Ltd | ペプチド誘導体 |
| JPH107553A (ja) * | 1996-03-21 | 1998-01-13 | Toutoushiyu Seizo Kk | 生体内ラジカル消去剤及び抗潰瘍剤 |
-
2003
- 2003-04-18 WO PCT/IB2003/001463 patent/WO2004091598A1/en not_active Ceased
- 2003-04-18 AU AU2003226582A patent/AU2003226582A1/en not_active Abandoned
-
2004
- 2004-04-15 US US10/553,807 patent/US20060167098A1/en not_active Abandoned
- 2004-04-15 JP JP2006506481A patent/JP2006523672A/ja not_active Withdrawn
- 2004-04-15 WO PCT/IB2004/001166 patent/WO2004091599A1/en not_active Ceased
- 2004-04-15 EP EP04727612A patent/EP1615630A1/en not_active Withdrawn
- 2004-04-15 CA CA002526899A patent/CA2526899A1/en not_active Abandoned
- 2004-04-15 BR BRPI0409456-5A patent/BRPI0409456A/pt not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10653778B2 (en) | Compositions and methods for treating chronic inflammation and inflammatory diseases | |
| EP1353696B1 (en) | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications | |
| US8211922B2 (en) | 1-methylnicotinamide derivatives and formulations for treatment of lipoprotein abnormalities | |
| JP2009525990A5 (https=) | ||
| US20060110444A1 (en) | Solid dosage form comprising a fibrate | |
| EP2584899B1 (en) | Niacin mimetics, and use thereof | |
| US20110092594A1 (en) | Use of nitrated lipids for treatment of lipid disorders and obesity, and lipid- and obesity-related conditions | |
| JP2006523672A5 (https=) | ||
| WO2015077154A1 (en) | Treatment of homozygous familial hypercholesterolemia | |
| JP2012520866A5 (https=) | ||
| CA2898017A1 (en) | Compositions and methods for treating chronic inflammation and inflammatory diseases | |
| JP2005501110A5 (https=) | ||
| WO2018065902A1 (en) | Combination compositions comprising fxr agonists for treating or preventing a fibrotic,cirrhotic disease or disorder | |
| AU2017328999B2 (en) | Combination of FXR agonists | |
| RU2019110779A (ru) | Новые схемы введения агонистов fxr | |
| JP2010513534A (ja) | Ｍｔｐインヒビターおよびコレステロール吸収インヒビターを含む組み合わせを用いて肥満症を処置する方法 | |
| WO2013169648A1 (en) | Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug | |
| KR20010042765A (ko) | Ｌ-카르니틴 또는 알카노일 ｌ-카르니틴 그리고 ｎａｄｈ및/또는 ｎａｄｐｈ가 포함되는 조성물 | |
| BRPI0409456A (pt) | métodos para o tratamento e/ou prevenção de doenças ligadas ao acúmulo de triglicerìdeos em tecidos e sangue, de doenças ligadas a uma falta de equilìbrio de colesterol em prejuìzo de colesterol hdl em tecidos e sangue, métodos de tratamento para diminuir os nìveis no sangue de triglicerìdeos, para equilibrar o nìvel no sangue e/ou tecidos de colesterol total em favor de colesterol hdl, para abaixar os nìveis de triglicerìdeo no fìgado, método para o tratamento ou prevenção de uma condição obesa, método de tratamento para a redução ou inibição do ganho de gordura corporal, método para aliviar a resistência ou restaurar a sensibilidade a insulina, uso de ácido beta-aminoisobutìrico, derivado, prodroga, metabólito ou complexo do mesmo, composição farmacêutica, composição nutricional, e, método para produzir redução de massa de gordura | |
| JP2008522972A (ja) | 脂肪酸エステルを有する安定性フェノフィブラート組成物 | |
| US6890941B1 (en) | Compositions containing HMG Co-A reductase inhibitors and policosanol | |
| EP3687536B1 (en) | Methods of treating hemochromatosis and respiratory disorders | |
| RU2024106180A (ru) | Композиции и способы предотвращения или снижения риска метаболического синдрома | |
| US20190262262A1 (en) | Composition and method for treatment of diabetes | |
| US20080207643A1 (en) | Composition for Treating Hyperlipaemia |